Status:

COMPLETED

Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome

Lead Sponsor:

Buddhist Tzu Chi General Hospital

Conditions:

Overactive Bladder

Eligibility:

All Genders

20-65 years

Phase:

PHASE4

Brief Summary

To investigate if oxybutynin ER adding on antimuscarinics is more effective than mono-antimuscarinic treatment for patients with refractory OAB

Detailed Description

* Introduction:Overactive bladder (OAB) is a symptom syndrome characterized by urgency frequency with or without urgency incontinence. Usually no metabolic or anatomical disorders can be found in pati...

Eligibility Criteria

Inclusion

  • Patients aged ≥20 years of male or female gender with OAB refractory to one antimuscarinics therapy
  • Patient or his/her legally acceptable representative has signed the written informed consent form

Exclusion

  • Patients with untreated bladder outlet obstruction, intrinsic sphincter deficiency, pelvic organ prolapse
  • Patients with history of urethral injury or transurethral surgery for prostate or bladder
  • Patients with severe cardiopulmonary disease and such as congestive heart failure, arrhythmia, poorly controlled hypertension, not able to receive regular follow-up
  • Patients with known active urinary tract infection, urinary stone or malignancy
  • Patients have laboratory abnormalities at screening including:
  • Aspartate aminotransferase (AST) \> 3 x upper limit of normal range.
  • Alanine aminotransferase (ALT) \> 3 x upper limit of normal range.
  • Patients have abnormal serum creatinine level \> 2 x upper limit of normal range.
  • Patients with urinary retention, PVR≥250 ml
  • Patients with any other serious disease or condition considered by the investigator not suitable for entry into the trial
  • Patients participated investigational drug trial within 1 month before entering this study
  • Patients with major psychiatric illness or drug abuse

Key Trial Info

Start Date :

March 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2017

Estimated Enrollment :

129 Patients enrolled

Trial Details

Trial ID

NCT01824420

Start Date

March 1 2013

End Date

February 1 2017

Last Update

March 8 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Buddhist Tzu Chi General Hospital

Hualien City, Taiwan, 970